
Keywords: آنتی بادی ضد سرطانی; Drug-induced liver injury; Hepatotoxicity; Gender differences; Drug property; Spontaneous adverse event reporting system; Liver events, and pharmacovigilance; DILI; drug-induced liver injury; DILIN; drug-induced liver injury network; HC; hepatocellular; C